This site is intended for healthcare professionals
News

Novartis announces long-term, relapse-free survival benefit for high-risk, stage III melanoma patients treated with Tafinlar + Mekinist following surgery.

Read time: 1 mins
Last updated:1st Jun 2020
Published:30th May 2020
Condition: Metastatic Melanoma
Type: drug
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest